The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

Triple therapy for COPD is more likely to offer cardiopulmonary benefits vs dual therapy, as indicated by NNT estimates for key cardiac outcomes.

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive ...

STOCKHOLM, SE / ACCESS Newswire / May 22, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, May 22, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, ...

Remote study conducted at Rutgers and elsewhere finds albuterol-budesonide mix cuts risk for mild cases and may let patients ...

The new data from PureTech come after the company reported successful results from the phase 2b Elevate study in December ...

Oxygen therapy can help COPD patients stay active with fewer symptoms, protect organs from oxygen deprivation damage, improve sleep quality and alertness, and potentially extend life span.

For initial treatment of symptomatic pulmonary sarcoidosis, methotrexate appeared to work as well as prednisone over 24 weeks ...

Treatment guidelines recommend systemic therapy, but some research indicates that thoracic reirradiation is an “attractive” option alone or alongside consolidative immunotherapy. Researchers ...